Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
Shi XC, Gruber JF, Ondari M, Lloyd PC, Freyria Duenas P, Clarke TC, Nadimpalli G, Cho S, Feinberg L, Hu M, Chillarige Y, Kelman JA, Forshee RA, Anderson SA, Shoaibi A.
Shi XC, et al. Among authors: forshee ra.
Vaccine. 2024 May 31;42(15):3486-3492. doi: 10.1016/j.vaccine.2024.04.051. Epub 2024 May 3.
Vaccine. 2024.
PMID: 38704258